RE:Had $30Million less than a year ago, $now $18MI haven't look at Willow in a while and the promise of Cannabis derived rare cannabinoids seems to have been stymied by a lack of progress of US federal reform. That said, we may at the very of a resurgence trend with the sector as a while. Safe Banking, HOPE, NJ 280e, HHS rescheduling review etc. Starting build momentum and will likely catch people off guard when plant touching MSOS spike first then it will drag up the rest. Still the cost of Capital is high and for Willow we will have to see whether it survives. I also have InMed Pharma which was most promising. I'm looking for minor cannabinoid sales to tick up.